Investment analysts at JPMorgan Chase & Co. assumed coverage on shares of EyePoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) in a report issued on Monday, MarketBeat reports. The firm set an “overweight” rating and a $35.00 price target on the stock. JPMorgan Chase & Co.‘s price objective indicates a potential upside of 40.51% from the […]
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report)’s share price fell 3.2% during mid-day trading on Friday . The stock traded as low as $21.85 and last traded at $22.12. 116,776 shares were traded during mid-day trading, a decline of 88% from the average session volume of 962,950 shares. The stock had previously closed at […]
EyePoint Pharmaceuticals (NASDAQ:EYPT – Free Report) had its target price reduced by HC Wainwright from $35.00 to $33.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for EyePoint Pharmaceuticals’ Q4 2023 earnings at ($0.40) EPS, FY2023 earnings at ($1.89) […]
EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) Director Ye Liu sold 1,910,500 shares of the business’s stock in a transaction on Thursday, January 11th. The shares were sold at an average price of $19.45, for a total value of $37,159,225.00. Following the completion of the sale, the director now owns 100,221 shares of the […]
WATERTOWN - EyePoint Pharmaceuticals, Inc. , a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced that.